Virtest Technologies SL, a spin-off from Universitat Pompeu Fabra, has successfully closed its first seed funding round, led by Grow Venture Partners through the FITA Fund, raising a total of €800,000. This investment will enable the consolidation of VIDAA, its innovative virtual simulation platform for surgical planning, and accelerate technological development with the goal of obtaining CE certification for commercialization in the European market.
VIDAA is a cloud-based platform developed by Virtest Technologies that enables the planning and simulation of structural heart interventions using virtual hearts personalized for each patient.
“VIDAA aims to support medical professionals not only in the planning phase but throughout every stage of the management of patients undergoing structural cardiac interventions, including postoperative care,” explains Jordi Mill, CEO of Virtest. “The platform combines advanced image analysis, artificial intelligence, and blood flow simulations to optimize device selection and anticipate potential complications. This results in more efficient and safer interventions, reducing procedure time and the risk of adverse effects.”
Thanks to this technology, medical teams can rehearse different scenarios prior to the intervention and define the most appropriate therapeutic strategy for each case.
The project began with the COMPILAAO proof-of-concept grant (2016–2019) within the Physense group at Universitat Pompeu Fabra, led by Professor Oscar Camara. Before its incorporation as a company in October 2024, the team had already secured €2.1 million in funding for research and development of the VIDAA platform and for predicting device-related thrombosis. The initiative was driven by Ainhoa Aguado, Jordi Mill, and Andy Olivares, who transformed years of academic research into a solution with real potential to impact clinical practice.
Since 2019, VIDAA has evolved to be used in live interventions since March 2023. To date, it has been successfully applied in nine real live clinical cases presented at international congresses. The most recent was a left atrial appendage closure procedure performed at Hospital Universitario de Salamanca, showcased during the RIICE 2025 congress.
Additionally, the retrospective IDEAL study—conducted in collaboration with nine hospitals and over 250 patients—has been completed, with its results to be presented in November at the prestigious London Valves 2025 congress.
The team comprises researchers and biomedical engineering experts who have been jointly developing this solution for years at UPF, united by the belief that the future of medical treatments must be personalized. They have formed a multidisciplinary core with extensive experience in computational modeling, medical imaging, and clinical collaboration.
Virtest also benefits from the financial advisory support of Intelectium, which assists in shaping the company’s growth and expansion strategy.
Based in Barcelona, Virtest Technologies is now preparing to validate its technology and obtain CE certification within one to two years, aiming to begin commercial deployment in hospitals across Spain and Europe, and later expand to international markets. During this phase, the company will continue collaborating with leading clinical centers to broaden validation and optimize integration into routine medical practice.
Virtest’s ultimate goal is to become a global benchmark in virtual simulation for cardiac procedures, contributing to safer, more precise, and more personalized medicine.
With a solid scientific foundation, a committed team, and clinically validated technology, Virtest embarks on this new stage determined to transform how professionals plan and execute cardiac interventions worldwide.
Grow Venture Partners is a venture capital management firm specialized in technology transfer, investing in early-stage companies emerging from universities and research centers, mainly within the DeepTech, MedTech, and Sustainability sectors. Its diverse and mission-driven team operates with a service mindset aimed at shaping better founders and, alongside them, creating sustainable wealth and employment with a positive global impact.
The FITA Fund is an initiative promoted by the Government of Catalonia and the European Investment Fund, managed by Grow Venture Partners. Its purpose is to support early-stage startups born from scientific research, with a particular focus on deep tech, medtech, and sustainability. FITA investments are backed by the European Union through the InvestEU program, with a total allocation of €50 million.
The fund was created to act as a bridge between research centers, universities, and the market. Its strategy focuses on supporting pre-seed, seed, and early-stage projects with a strong technological foundation, mainly stemming from Catalonia’s R&D ecosystem. All announced investments have been made in startups originating from scientific excellence environments and represent outstanding cases of successful technology transfer.
cloud technology axon
Xcalibur Smart Mapping, recognised as the global leader in airborne...
